Revance Therapeutics Statistics
Total Valuation
TNXP has a market cap or net worth of $288.90 million. The enterprise value is $157.75 million.
Important Dates
The next estimated earnings date is Friday, August 15, 2025, after market close.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TNXP has 7.41 million shares outstanding. The number of shares has increased by 15,588.77% in one year.
| Current Share Class | 7.41M |
| Shares Outstanding | 7.41M |
| Shares Change (YoY) | +15,588.77% |
| Shares Change (QoQ) | +161.86% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 11.30% |
| Float | 7.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.59 |
| Forward PS | 8.76 |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.31, with a Debt / Equity ratio of 0.00.
| Current Ratio | 12.31 |
| Quick Ratio | 11.21 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -91.44% and return on invested capital (ROIC) is -30.30%.
| Return on Equity (ROE) | -91.44% |
| Return on Assets (ROA) | -27.59% |
| Return on Invested Capital (ROIC) | -30.30% |
| Return on Capital Employed (ROCE) | -40.09% |
| Revenue Per Employee | $123,963 |
| Profits Per Employee | -$1.63M |
| Employee Count | 81 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.37% in the last 52 weeks. The beta is 2.07, so TNXP's price volatility has been higher than the market average.
| Beta (5Y) | 2.07 |
| 52-Week Price Change | -21.37% |
| 50-Day Moving Average | 38.54 |
| 200-Day Moving Average | 25.04 |
| Relative Strength Index (RSI) | 46.37 |
| Average Volume (20 Days) | 1,426,374 |
Short Selling Information
The latest short interest is 1.19 million, so 16.05% of the outstanding shares have been sold short.
| Short Interest | 1.19M |
| Short Previous Month | 1.21M |
| Short % of Shares Out | 16.05% |
| Short % of Float | 16.06% |
| Short Ratio (days to cover) | 1.60 |
Income Statement
In the last 12 months, TNXP had revenue of $10.04 million and -$131.93 million in losses. Loss per share was -$59.66.
| Revenue | 10.04M |
| Gross Profit | 2.99M |
| Operating Income | -72.45M |
| Pretax Income | n/a |
| Net Income | -131.93M |
| EBITDA | -69.54M |
| EBIT | -72.45M |
| Loss Per Share | -$59.66 |
Full Income StatementBalance Sheet
The company has $131.72 million in cash and $563,000 in debt, giving a net cash position of $131.15 million or $17.71 per share.
| Cash & Cash Equivalents | 131.72M |
| Total Debt | 563,000 |
| Net Cash | 131.15M |
| Net Cash Per Share | $17.71 |
| Equity (Book Value) | 180.40M |
| Book Value Per Share | 26.23 |
| Working Capital | 137.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.93 million and capital expenditures -$18,000, giving a free cash flow of -$59.95 million.
| Operating Cash Flow | -59.93M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -59.95M |
| FCF Per Share | -$8.09 |
Full Cash Flow StatementMargins
| Gross Margin | 29.81% |
| Operating Margin | -721.51% |
| Pretax Margin | -1,313.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TNXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15,588.77% |
| Shareholder Yield | -15,588.77% |
| Earnings Yield | -45.66% |
| FCF Yield | -20.75% |
Analyst Forecast
The average price target for TNXP is $70.00, which is 79.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $70.00 |
| Price Target Difference | 79.44% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 5, 2025. It was a reverse split with a ratio of 1:100.
| Last Split Date | Feb 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
TNXP has an Altman Z-Score of -4.13 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.13 |
| Piotroski F-Score | 2 |
